More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (+25.0% Growth)
- Ratings (10.0 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (11/4/15 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 38.83M
Marketable securities 15M
Proceeds from sale of RXi, received January 6, 2011
Receivable 5.18M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 14.2K
Prepaid expenses and other current assets 976.33K
Total current assets 60M
Equipment and furnishings, net 879.36K
Goodwill 183.78K
Other assets 1.57M
Total assets 62.63M
Current liabilities:
Accounts payable 5.33M
Accrued expenses and other current liabilities 10.38M
Warrant liabilities 4.57M
Total current liabilities 20.27M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 55.93K
Additional paid-in capital 380.64M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.61M
Accumulated deficit -335.72M
Total stockholders' equity 42.36M
Total liabilities and stockholders' equity 62.63M